BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Early stage cardio data from Verve bump the stock
Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, including bringing partner Eli Lilly and Co. in a...

More in BioWorld

BioWorld MedTech

Australian researchers discover new compound to treat long COVID
Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans. Developed...

More in BioWorld MedTech

BioWorld Science

Pretzel Therapeutics narrows the therapeutic gap for PolG disease
Researchers from Pretzel Therapeutics Inc. and the University of Gothenburg have published new insights on how mutations in the POLG gene affect its functionality and are...

More in BioWorld Science

BioWorld Asia

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetes
Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2 diabetes...

More in BioWorld Asia

BioWorld Insider Podcast

As biopharma investments stumble, med tech surges: This year’s med-tech investments include $2.76B via 56 transactions in January alone. BioWorld MedTech Editor Annette Boyle discusses why the sector is performing well year to date.